Katherine Call, Ph.D.
Katherine M. Call has extensive experience in the fields of biologics and genomics, having identified and validated disease genes and drug targets and advanced molecules into development in several therapeutic areas. She is currently Senior Director and Head, Proteogenomics, a newly established group with a strong translational science component in the Sanofi-Genzyme R&D Center. Dr. Call was Head of US Biologics Research from 2010 - mid 2012 and led the establishment of Sanofi Discovery Biotherapeutics globally from 2005 - 2007. She joined Sanofi as Head of Molecular Genomics at the Cambridge Research Center in 2000 and was subsequently appointed Global Head, Genomics Technology Transfer/ Management. As a co-founder of the Cambridge Genomics Research Center in 1997, Dr. Call’s team established molecular genomic platforms and applied these to bone and cancer projects to identify and validate therapeutic targets. This joint venture demonstrated strong value in a short period and was acquired by Sanofi in 2000. She also has experience with external partners, having initiated External Research Strategy and Innovation in the greater Boston area, identified external biologics opportunities and been involved in strategic alliances.
Dr. Call holds a Bachelor degree in Biology, awarded with highest honors, from the University of California at Santa Cruz. At MIT, she earned a Ph.D. in Applied Biology / Genetic Toxicology and did post-doctoral training in human genetics and genomics at the Koch Center for Cancer Research. She was awarded a NIH postdoctoral fellowship in which she successfully cloned a Wilms’ tumor gene. A landmark accomplishment - the second tumor suppressor gene and one of the first disease genes isolated based on genetic map information and genomics approaches.
She was a faculty at Harvard School of Public Health and Harvard Medical School, a key investigator on large NIH Human Genome Center grants for mapping and sequencing of chromosomes 10 and 11, has published 35 scientific papers and holds issued patents on a Wilms’ tumor gene, bone disease genes and genomics technology methods. Dr. Call has served extensively in external scientific communities - on grant review panels, as a committee member and Deputy Editor for human chromosome 10 and in a consultant and advisory board capacity to life sciences companies & organizations.